GNI Group (3G6) Price & Analysis

Compare

0 Followers

3G6 Stock Chart & Stats

€12.70

€0.40(2.20%)

At close: Jan 08 4:00 PM EST

€12.70

€0.40(2.20%)

Day’s Range― - ―

52-Week Range€8.80 - €26.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€1.07B

Enterprise Value€165.11B

Total Cash (Recent Filing)€21.10B

Total Debt (Recent Filing)€6.36B

Price to Earnings (P/E)―

Beta1.09

Next Earnings

May 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding55,685,127

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)2.52

Price to Sales (P/S)4.71

P/FCF Ratio-46.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.18

Revenue Forecast (FY)€231.53M

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthLow leverage and materially higher equity provide durable financial resilience. With debt-to-equity around 0.13, the company has optionality to raise debt if needed, a longer runway to fund R&D and operations, and greater ability to absorb short-term cash stress without immediate dilutive equity financing.

Sustained Revenue GrowthA multi-year revenue growth trend and the 2025 rebound indicate persistent market demand and commercial traction. For a biotech, continued top-line expansion helps spread fixed costs, improves operating leverage potential, and increases the likelihood that scaling revenue will translate into durable margin recovery over the medium term.

High Gross MarginsVery high gross margins point to advantaged product economics or pricing power. This structural margin strength means that if operating expenses stabilize, revenue growth can flow quickly to operating profit and free cash flow, supporting long-term sustainability once variability eases.

Bears Say

Persistent Cash BurnTwo consecutive years of negative operating and free cash flow indicate the business is not currently self-funding. Persistent cash burn increases reliance on external financing, raises dilution and refinancing risk, and constrains the firm's ability to invest in growth or withstand prolonged R&D and commercialization cycles.

2025 Profitability Swing To LossesA material swing to net losses in 2025 reduces internal funding capacity and signal weaker earnings quality. Continued losses weaken capital efficiency, heighten the need for additional funding, and make long-term planning harder, pressuring the firm's ability to convert high gross margins into sustainable net profitability.

Volatile Earnings & Cash GenerationMarked volatility between strong cash generation in 2023 and material weakening in 2024–25 reduces forecasting reliability. For a development-driven biotech, this unpredictability increases execution and financing risk, complicates capital allocation, and undermines confidence that revenue and margin recoveries will be steady.

GNI Group News

GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen

An announcement from GNI Group ( ($JP:2160) ) is now available. GNI Group, through its U.S. affiliate Gyre...

14h ago

GNI Group Revises Parent-Only Results After Tax and Valuation Adjustments

GNI Group ( ($JP:2160) ) has provided an update. GNI Group Ltd. has announced corrections to previously disclosed...

9d ago

GNI Group Revamps Board Slate With New Independent Director Ahead of AGM

GNI Group ( ($JP:2160) ) has shared an update. GNI Group Ltd. has proposed a slate of director...

9d ago

GNI Group Revises FY2025 Results After Overstated CFC Tax Expense

An update from GNI Group ( ($JP:2160) ) is now available. GNI Group has announced a partial correction...

9d ago

GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal

An update from GNI Group ( ($JP:2160) ) is now available. GNI Group’s Nasdaq-listed subsidiary Gyre Therapeutics has...

11d ago

GNI Group Swings to Non-Consolidated Loss on Absence of One-Off Gain and Forward Transaction Hit

GNI Group ( ($JP:2160) ) has issued an update. GNI Group Ltd., a biopharmaceutical company listed on the...

28d ago

GNI Group Swings to Loss in FY2025 Despite Higher Revenue and Stronger Equity Base

GNI Group ( ($JP:2160) ) has issued an update. GNI Group reported FY2025 consolidated revenue of ¥26.84 billion,...

28d ago

GNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has postponed the disclosure of its full-year...

28d ago

GNI Group Explains Acquisition Plans, Earnings Revision and F351 Disclosure Strategy

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has addressed a series of investor questions...

29d ago

3G6 Earnings this Week: How Will it Perform?

GNI Group (3G6) is scheduled to report 4th quarter earnings on 02/13/2026. Regarding Q4 estimates, Wall Street analysts...

1M ago

3G6 FAQ

What was GNI Group Ltd.’s price range in the past 12 months?

GNI Group Ltd. lowest stock price was €8.80 and its highest was €26.00 in the past 12 months.

What is GNI Group Ltd.’s market cap?

GNI Group Ltd.’s market cap is €1.07B.

When is GNI Group Ltd.’s upcoming earnings report date?

GNI Group Ltd.’s upcoming earnings report date is May 18, 2026 which is in 66 days.

How were GNI Group Ltd.’s earnings last quarter?

GNI Group Ltd. released its earnings results on Feb 13, 2026. The company reported -€0.406 earnings per share for the quarter, missing the consensus estimate of €1.225 by -€1.631.

Is GNI Group Ltd. overvalued?

According to Wall Street analysts GNI Group Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does GNI Group Ltd. pay dividends?

GNI Group Ltd. does not currently pay dividends.

What is GNI Group Ltd.’s EPS estimate?

GNI Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does GNI Group Ltd. have?

GNI Group Ltd. has 55,685,127 shares outstanding.

What happened to GNI Group Ltd.’s price movement after its last earnings report?

GNI Group Ltd. reported an EPS of -€0.406 in its last earnings report, missing expectations of €1.225. Following the earnings report the stock price went down -3.676%.

Which hedge fund is a major shareholder of GNI Group Ltd.?

Currently, no hedge funds are holding shares in DE:3G6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

GNI Group Ltd.

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.